Omni Bio Pharmaceutical (OMBP) Stock Price, News & Analysis

Company Overview

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.04
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OMBP Stock Analysis - Frequently Asked Questions

How have OMBP shares performed this year?

Omni Bio Pharmaceutical's stock was trading at $0.0010 at the beginning of the year. Since then, OMBP shares have increased by 0.0% and is now trading at $0.0010.
View the best growth stocks for 2025 here.

How do I buy shares of Omni Bio Pharmaceutical?

Shares of OMBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Omni Bio Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Omni Bio Pharmaceutical investors own include Alumina (AWCMY), Xenon Pharmaceuticals (XENE), Yamana Gold (AUY), Asensus Surgical (ASXC), Preferred Apartment Communities (APTS), Ally Financial (ALLY) and Apartment Income REIT (AIRC).

Company Calendar

• Today: 5/31/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OMBP
• CIK: 1389870
• Web: www.omnibiopharma.com
• Phone: 970-237-5178
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A